0001209191-19-006611.txt : 20190201
0001209191-19-006611.hdr.sgml : 20190201
20190201190652
ACCESSION NUMBER: 0001209191-19-006611
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190131
FILED AS OF DATE: 20190201
DATE AS OF CHANGE: 20190201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sandison Taylor
CENTRAL INDEX KEY: 0001702287
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36912
FILM NUMBER: 19561301
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cidara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001610618
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461537286
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-752-6170
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: K2 THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140611
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-31
0
0001610618
Cidara Therapeutics, Inc.
CDTX
0001702287
Sandison Taylor
6310 NANCY RIDGE DR, SUITE 101
SAN DIEGO
CA
92121
0
1
0
0
Chief Medical Officer
Common Stock
2019-01-31
4
A
0
6000
0.00
A
50722
D
Restricted Stock Unit
2019-01-31
4
M
0
14000
0.00
A
2022-01-01
Common Stock
14000
14000
D
1/3rd of the total number of shares subject to the restricted stock unit shall vest on each January 1 of 2020, 2021 and 2022.
Includes 323 and 3,704 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2017 and May 18, 2018, respectively.
Restricted stock units convert into common stock on a one-for-one basis.
The shares shall vest upon the achievement of various clinical and corporate milestones.
/s/ Jessica Oien, Attorney-in-fact
2019-02-01
EX-24.4_829585
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all, by these presents, that the undersigned hereby constitutes and
appoints each of Jeffrey Stein, Jessica Oien, James Levine and Brady Johnson,
signing individually, the undersigned's true and lawful attorneys-in fact and
agents to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of Cidara Therapeutics, Inc.
(the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules
thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact shall no longer be employed by the
Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 28th day of January, 2019.
/s/ TAYLOR SANDISON
NAME: TAYLOR SANDISON